免疫介导炎症性皮肤病跨学科诊疗的结局指标:范围综述
共报告49种不同指标,其中38种仅被一项研究使用。除少数常用指标外,结局指标异质性大,难以跨研究比较,提示需就核心结局指标集达成共识。
要点
- 跨学科诊疗研究集中于银屑病和特应性皮炎,报告结局指标异质性大。
- 49种结局指标中38种仅一项研究使用,限制跨研究比较。
- 建议就跨学科诊疗的核心结局指标集达成共识以提升可比性。
核心结论
- 尽管已有多个跨学科诊疗模型研究,但评估其对临床医生报告和患者报告结局指标影响的研究较少。
- 所用结局指标异质性大,给跨研究比较带来挑战。
- 需要就跨学科诊疗的核心结局指标集达成共识,以建立共同语言并增强研究可比性。
研究设计与样本
- 纳入标准为研究涉及皮肤科医生参与的免疫介导炎症性皮肤病跨学科诊疗,并报告临床医生报告或患者报告结局指标。
- 由两名独立评审员按标题、摘要和全文筛选,分歧由第三名评审员解决。
- 最终纳入14项研究。
主要发现
- 9项研究探讨银屑病跨学科诊疗,4项探讨特应性皮炎,1项探讨化脓性汗腺炎。
- 6项银屑病研究考察皮肤科-风湿科联合门诊,4项研究探索与精神科医生或心理师的协作。
- 其余跨学科诊疗模型多样。
- 共报告49种不同的临床医生报告和患者报告结局指标,其中38种仅被一项研究报告。
- 皮肤科生活质量指数被12项研究使用,体表面积被4项研究使用。
关键数值与推荐
- 银屑病面积和严重程度指数被所有银屑病研究使用。
- 湿疹面积和严重程度指数或特应性皮炎评分被所有特应性皮炎研究使用。
- 皮肤科生活质量指数被12项研究使用。
- 体表面积被4项研究使用。
临床怎么用
- 临床采用跨学科诊疗时,可参考银屑病和特应性皮炎中较一致使用的疾病严重程度指标及皮肤科生活质量指数。
- 需注意其他结局指标尤其是患者报告结局指标变异大,选择时需谨慎。
- 推动使用标准化核心结局指标集有助于积累可比证据并支持指南制定。
局限性
- 仅纳入报告临床医生报告或患者报告结局指标的研究,可能遗漏其他跨学科诊疗评估维度。
- 纳入研究数量有限(14项),且跨学科诊疗模型多样,限制汇总分析。
- 未报告纳入研究的偏倚风险或证据质量评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a growing trend towards interdisciplinary care (IC) for the management of immune-mediated inflammatory skin diseases (skIMIDs). However, an overview of instruments used to evaluate whether IC is superior to usual care is currently lacking. OBJECTIVES: This scoping review aims to gain insight into clinician- and patient-reported outcome measures (ClinROMs and PROMs) used in IC for skIMIDs. METHODS: A comprehensive literature search was conducted by screening PubMed, Web of Science and Embase databases from their inception until October 2024. To be eligible, studies needed to have investigated IC for skIMIDs involving dermatologists, and have reported either ClinROMs or PROMs. Two independent reviewers screened all records by title, abstract and full text, with conflicts resolved by a third reviewer. RESULTS: Fourteen studies were included in this review. Nine investigated IC for psoriasis (PsO), four for atopic dermatitis (AD) and one for hidradenitis suppurativa. Six PsO studies examined combined dermatology-rheumatology clinics, while four studies explored collaborations with psychiatrists or psychologists for PsO or AD. The remaining IC models were diverse. A total of 49 different ClinROMs and PROMs were reported across the included studies, with 38 being reported by only one study. Except for the Dermatology Life Quality Index (used by 12 studies), body surface area (used by four studies), Psoriasis Area and Severity Index (used by all PsO studies), and Eczema Area and Severity Index or SCORing Atopic Dermatitis (used by all AD studies), the reported ClinROMs and particularly PROMs vary widely. CONCLUSIONS: Although several studies describe IC models for skIMIDs, few investigated their impact on ClinROMs or PROMs. The heterogeneous outcomes used pose a challenge for comparison across studies. This review highlights the need for consensus on a core set of outcome measures for IC in skIMIDs to create a common language among the healthcare providers involved, and enhance comparability between studies. Implementing standardized outcome measures for IC in skIMIDs could contribute to the development of evidence-based guidelines and ultimately, improve patient care. Immune-mediated inflammatory skin diseases (skIMIDs) is the name for a group of conditions. They are characterized by chronic inflammation. SkIMIDs may affect different organ systems such as the skin, digestive system and joints. Moreover, skIMIDs can have a negative impact on mental well-being. To address all these problems, several medical specialists can work together. This is called interdisciplinary care (IC). Nowadays IC is being used more often to help patients with skIMIDs. But we don’t know if these patients are doing better. An overview of instruments evaluating IC in skIMIDs is currently lacking. We performed a literature review to see how ‘outcome measures’ are used in IC for skIMIDs. We looked at clinician- and patient-reported outcome measures (ClinROMs and PROMs). ClinROMs are assessments about patients’ health status made by clinicians. PROMs are self-rated by patients. They reflect how patients feel or function in relation to their condition. We searched for studies examining IC models for skIMIDs. All 14 studies measuring ClinROMs or PROMs were included. A total of 49 different outcome measures were reported across the included studies. Of those, 38 were reported by only one study. Some validated outcome measures were used consistently. This was the case for disease severity measures for psoriasis and atopic dermatitis, as well as quality of life monitoring through the Dermatology Life Quality Index. The other reported outcome measures varied widely. Our findings show that we need to agree on a core set of outcome measures for IC in skIMIDs. If we can standardize outcome measures, we can collect data consistently. This improves the comparability across studies. Implementing standardized outcome measures for IC in skIMIDs could contribute to the development of evidence-based guidelines. Ultimately, this may result in better patient care.
引用
- Lemarcq L, Reynaert V, Van den Steen E, et al. Outcome measures for interdisciplinary care in immune-mediated inflammatory skin diseases: a scoping review. Br J Dermatol. 2025. PMID: 40249773. doi:10.1093/bjd/ljaf153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。